Canaccord raised the firm’s price target on Alnylam (ALNY) to $415 from $390 and keeps a Buy rating on the shares. The firm said they delivered an excellent 2Q25 driven by higher-than-expected Amvuttra sales leading to increased guidance and raised estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Cautious Optimism: Alnylam Pharma’s Strong TTR Franchise Growth and Hold Rating
- Alnylam price target raised to $460 from $329 at Barclays
- Alnylam Pharmaceuticals Reports Strong Q2 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Partnerships Justify Buy Rating
- Alnylam Pharma’s Strong Q2 2025 Performance and Raised Guidance Justify Buy Rating and Increased Price Target